Lakewood-Amedex Biotherapeutics Inc. LABT 深 沪
已收盘 10-30 16:00:00 美东时间
0.20
-0.037
-15.72%
华盛通- 最 高0.22
- 今 开0.197
- 成交量 191.22万股
- 最 低 0.195
- 昨 收 0.2373
- 总市值 47.39万
- 52周最高 98.20
- 市盈率 静 --
- 换手率 80.70%
- 52周最低 0.195
- 委 比 92.31%
- 总股本 236.97万
- 历史最高 98.20
- 量 比 0.13
- 振 幅 10.54%
- 历史最低 0.195
- 每 手 1
- 风险率 14.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
10-29 12:30
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Matthew Shea initiated coverage on Alignment Healthcare Inc (NASDAQ:ALHC) with a ...
10-28 20:38
Lakewood-Amedex Biotherapeutics Presents Research Highlighting Antimicrobial Profile Of Nu-3, Lead Clinical Candidate, At IDWeek 2026; Topline Data From Trial Expected In Q1 2027
Research highlights Nu-3's rapid bactericidal activity against clinically relevant resistant pathogens and its potential as a topical treatment for infected diabetic foot ulcers SARASOTA, Fla., Oct. 21, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", ))), a ...
10-21 20:07
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fa...
10-01 20:02
Lakewood-Amedex Biotherapeutics Announces Minimum Inhibitory Concentration Data From Recent Clinical Isolates Of Nu-3 Demonstrates Consistent Activity Against All Organisms
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced positive Minimum Inhibitory Concentration (MIC)...
09-28 20:09
Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) on Thursday said it dosed the first patient in its Phase 2a clinical trial evaluating Nu-3 for mildly infected diabetic foot ulcers. The initiation of patient dosing represents a significant clinical milestone for Lakewood-Amedex Biotherapeutics as ...
09-24 22:50
Lakewood-Amedex Registers Resale Of Up To 4,512,400 Shares Of Common Stock By Selling Stockholder
LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. 4,512,400 Shares of Common Stock This prospectus relates to the resale from time to time of up to 4,512,400 shares of common stock, par value $0.0001 per share, of Lakewood-Amedex Biotherapeutics Inc., or Common Stock, by a certain selling stockholder with ...
09-19 05:44
Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of 27 cents per share, which beat the analyst consensus estimate of 20 cents per share. The company repor...
09-01 16:35
Lakewood-Amedex Biotherapeutics Announces Resistance Data For Nu-3 In Alignment With Presidential Advisory Council On Combating Antibiotic Resistant Bacteria
Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance. SARASOTA, Fla., July 22, 2026 /PRNewswire/ -- Lakewood-Amedex B...
07-22 20:04
Lakewood-Amedex Biotherapeutics Awarded New Australian Patent Protecting Bisphosphocin Compounds That Are Being Explored In A Range Of Antimicrobial Infections
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", ))), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the expansion of the Company's paten...
06-22 20:16
